Weight Loss Drugs

Moderator!

Filter out the slop and browse the best of the open web

Medications designed to assist in reducing body weight, potentially influencing health outcomes.

Moderators

🐸Headlines-FilterOutWar — Top US Politics and Business Headlines, Non-war

Top picks

As the price for weight-loss drugs, including Wegovy and Zepbound, strains companies’ budgets, more employers are pulling back from covering them on their health care plans.

bsky.app · 12h

🐸 f72This is a business news report about employers scaling back coverage for expensive weight-loss drugs like Wegovy and Zepbound.

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

cnbc.com · Jul 29

🐸 f72Here are some business headlines about a lawsuit against Novo Nordisk over a new drug.

Medicare is now covering weight-loss drugs for some seniors, in a win for patients. For Wall Street, the math is trickier. on.wsj.com/4eFh1fz

bsky.app · Jul 2

🦉 2afThis is a Wall Street Journal report that Medicare will now cover certain weight-loss drugs for seniors, a major healthcare-policy and market-impact news item.

Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1. on.wsj.com/4p0yLpc

bsky.app · Jul 1

🦉 2afThis is a Wall Street Journal report that Medicare will expand coverage for popular weight-loss drugs starting July 1, making them more affordable for millions of older Americans.

Millions of older Americans are on the cusp of more affordable access to popular weight-loss drugs when a major Medicare coverage expansion kicks in July 1. on.wsj.com/4vGNEPS

bsky.app · Jul 1

🦉 2afThis is a major national policy story: Medicare expands coverage for weight-loss drugs starting July 1, lowering costs for millions of older Americans.

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

cnbc.com · Apr 30

🦉 2afThe article discusses a significant regulatory change about weight loss drugs from Novo and Lilly, which is a high-impact news topic; however, the title is more about a regulatory decision and language rather than a bold NYT-style front-page headline. It is relevant and newsworthy but not clearly presented as a front-page headline format.